Intra-aortic balloon pump (IABP) counterpulsation improves cerebral perfusion in patients with decreased left ventricular function by Pfluecke, C. et al.
 
 
 
 
 
Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / 
This is a self-archiving document (published version):  
 
 
 
 
 
 
 
 
 
 
Diese Version ist verfügbar / This version is available on:  
https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-353642 
 
 
„Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. 
Nationallizenz frei zugänglich.“ 
 
This publication is openly accessible with the permission of the copyright owner. The permission is 
granted within a nationwide license, supported by the German Research Foundation (abbr. in German 
DFG). 
www.nationallizenzen.de/ 
 
 
C. Pfluecke, M. Christoph, S. Kolschmann, D. Tarnowski, M. Forkmann, S. Jellinghaus,     
D. M. Poitz, C. Wunderlich, R. H. Strasser, S. Schoen, K. Ibrahim 
Intra-aortic balloon pump (IABP) counterpulsation improves cerebral 
perfusion in patients with decreased left ventricular function 
 
Erstveröffentlichung in / First published in: 
Perfusion. 2014, 29(6), S. 511 – 516 [Zugriff am: 19.08.2019]. SAGE journals. ISSN 1477-111X. 
DOI: https://doi.org/10.1177/0267659114525218 
 
Perfusion
2014, Vol. 29(6) 511 –516
© The Author(s) 2014
Reprints and permissions: 
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0267659114525218
prf.sagepub.com
Introduction
Stroke represents a rapid loss of brain function, which 
most commonly results from an occlusion of a major 
artery in the brain. This typically leads to the death of all 
cells within the affected tissue and, in sequence, leads to 
neurological dysfunction.1 After ischemic stroke imme-
diate onset, it is important to provide adequate treat-
ment with systemic thrombolysis or intra-arterial rescue 
procedures in order to restore cerebral blood flow.2,3 
Unfortunately, the majority of stroke patients remain 
ineligible for these therapies because of late hospital 
arrival. The ischemic cerebral infarction may be sur-
rounded by collaterally perfused areas, the penumbra, 
in which vessels show an impaired autoregulation.3 The 
current goal of treatment is to increase cerebral blood 
flow in the ischemic penumbra, which might not be 
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Abstract
Background: The current goal of treatment after acute ischemic stroke is the increase of cerebral blood flow (CBF) 
in ischemic brain tissue. Intra-aortic balloon pump (IABP) counterpulsation in the setting of cardiogenic shock is able 
to reduce left ventricular afterload and increase coronary blood flow. The effects of an IABP on CBF have not been 
sufficiently examined. We hypothesize that the use of an IABP especially enhances cerebral blood flow in patients with 
pre-existing heart failure.
Methods: In this pilot study, 36 subjects were examined to investigate the effect of an IABP on middle cerebral artery 
(MCA) transcranial Doppler (TCD) flow velocity change and relative CBF augmentation by determining velocity time 
integral changes (∆VTI) in a constant caliber of the MCA compared to a baseline measurement without an IABP. Subjects 
were divided into two groups according to their left ventricular ejection fraction (LVEF): Group 1 LVEF >30% and Group 
2 LVEF ≤30%.
Results: Both groups showed an increase in CBF using an IABP. Patients with a LVEF ≤30% showed a significantly higher 
increase of ∆VTI in the MCA under IABP augmentation compared to patients with a LVEF >30% (20.9% ± 3.9% Group 
2 vs.10.5% ± 2.2% Group 1, p<0,05). The mean arterial pressure (MAP) increased only marginally in both groups under 
IABP augmentation.
Conclusions: IABP improves cerebral blood flow, particularly in patients with pre-existing heart failure and highly impaired 
LVEF. Hence, an IABP might be a treatment option to improve cerebral perfusion in selected patients with cerebral 
misperfusion and simultaneously existing severe heart failure.
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irreversibly damaged, but shows impaired perfusion. 
Many efforts have been made to improve cerebral perfu-
sion as there might be salvageable brain tissue up to 8 to 
24 hours after the symptoms occurred. Neither hemodi-
lution nor treatment with vasodilators, such as pentoxi-
fylline, have been shown to improve outcome after 
stroke and, therefore, are not recommended for the 
treatment of patients with acute ischemic stroke.4 
Inducing hypertension to increase cerebral blood flow is 
suggested to improve neurologic outcome.5 Patients 
with acute ischemic stroke treated with intravenous 
phenylephrine showed an improvement in neurological 
symptoms in 33% of the population.6 Unfortunately, 
patients with decreased left ventricular function and 
congestive heart failure were excluded in this setting.
The occurrence of acute ischemic stroke and co-
existing heart failure is difficult to treat. Patients with a 
history of myocardial infarction, decreased left ventric-
ular function7 and consecutive left ventricular or left 
atrial thrombus are at a greater risk for stroke.8,9 Due to 
lower cardiac output (CO), perfusion of the ischemic 
cerebral areas might be further reduced, which has been 
proven by animal and human studies.10 Administration 
of vasopressors alone could have serious side effects, 
worsening pre-existing heart failure. How can we opti-
mize the cerebral blood flow in patients with severely 
impaired left ventricular function?
Patients with cardiogenic shock (CS) are unable to 
maintain adequate CO. An increase in systemic vascular 
resistance (SVR) is typical and can worsen the heart fail-
ure by increasing the ventricular afterload.
IABP counterpulsation is the most commonly used 
mechanical support for the treatment of CS in selected 
patients.11,12 The IABP, which is placed in the descend-
ing aorta via femoral arterial access, enhances diastolic 
pressure in the aortic arch by inflation of the balloon in 
diastole and reduces left ventricular afterload by active 
deflation in systole. The use of an IABP has shown a 
temporal improvement in CO and lower SVR.13 
Furthermore, positive effects on microvascular perfu-
sion14 and renal blood flow14,15 could be demonstrated 
in patients with CS who were on IABP. Several studies 
have demonstrated the importance of establishing and 
maintaining a patent infarct-related artery in the setting 
of acute myocardial infarction complicated by cardio-
genic shock.16 The implantation of an intra-aortic bal-
loon pump (IABP) has been shown to be able to enhance 
the success of coronary thrombolysis in the setting of 
acute myocardial infarction,17 but did not significantly 
reduce 30-day mortality in patients with signs of CS 
after acute myocardial infarction with an early revascu-
larization strategy. The patients in this study by Thiele et 
al.18 had an average LVEF of 35%. In another rand-
omized trial, the elective use of an IABP during high-
risk percutaneous coronary interventions led to a 34% 
relative reduction in all-cause, long-term mortality in 
patients with severe ischemic cardiomyopathy. These 
patients had a more impaired left ventricular function 
(LVEF on average 23.6%).19 Hence, the use of an IABP 
might prevent re-occlusion by augmenting coronary 
perfusion in combination with thrombolytic therapy,20 
whereas it failed to show any benefit in patients with 
only moderate impaired LVEF who are treated with pri-
mary angioplasty.21
Taking the similarity of both cerebral and myocar-
dial ischemia into consideration, the implantation of 
an IABP after acute ischemic stroke and thrombolytic 
therapy might be feasible for improving outcome in 
these patients by increasing patency rates of the infarct-
related artery. Furthermore, the use of an IABP could 
enhance cerebral blood flow, especially in the penum-
bra, and may provide a new treatment option in 
patients with acute ischemic stroke and simultaneously 
existing heart failure. However, it is not clear which 
patients might profit from the IABP by augmenting 
cerebral perfusion.
The aim of this pilot study was to examine the hemo-
dynamic effects of an IABP on cerebral blood flow in 
patients with severely impaired left ventricular func-
tion.
Methods
Thirty-six subjects were examined to determine the 
effect of the IABP on middle cerebral artery (MCA) 
transcranial Doppler (TCD) flow velocity change and 
cerebral flow augmentation compared to a baseline 
measurement without an IABP. All the patients were 
undergoing coronary angiography, either due to acute 
coronary syndrome or elective high-risk percutaneous 
coronary intervention (PCI). The IABP was inserted in 
the cardiac catheterization laboratory via the femoral 
artery using an 8.0 Fr intra-aortic balloon catheter 
(Fidelity IAB Catheter, Maquet Cardiopulmonary AG, 
Hirrlingen, Germany). Afterwards, the patients were 
transferred to the intensive care unit. The balloon size 
was adapted to the subject’s height. IABP inflation and 
deflation timing was optimized automatically by the 
IABP. The position of the IABP was controlled by chest 
X-ray.
Measurements of transcranial blood flow velocities 
were performed as previously described.22 To determine 
the effect of the IABP on MCA cerebral flow, subjects 
were on 1:1 augmentation by IABP for at least one hour 
before the measurements of MCA TCD flow velocity 
change and velocity time integral (Figure 1) were per-
formed (Phillips HD 11, S3-1, 3 to 1 MHz, Philips 
GmbH, Herrsching, Germany).
Afterwards, the IABP was paused for 1 minute and 
changes in the parameters mentioned above were 
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measured. The cerebral blood flow (CBF) in the MCA 
could be calculated as:
 CBF VTI HR VD= ∗ ∗π / 4
VTI: velocity time integral; HR: heart rate; VD: vessel 
diameter.
Measurements were taken in the same section of the 
MCA to ensure a constant vessel diameter. Differences 
in heart rate in the measurements with and without 
IABP were negligible (Table 1). Therefore, the relative 
change in cerebral blood flow corresponds to the rela-
tive change of VTI.
 ∆ ∆CBF VTI∼
The subjects were divided into two groups according 
to their ejection fraction (Group 1: LVEF >30%, 
Group 2: LVEF ≤30%). The chosen cut-off point for 
the left ventricular ejection fraction (LVEF) of 30% 
reflects the transition to severe impairment of 
systolic left heart function. LVEF was measured 
by echocardiography following the Simpson 
method.
Statistical analyses were performed by a statisti-
cian using SPSS v.19 (IBM SPSS Inc., Austin, TX). 
The distribution of continuous data was examined 
using the Kolmogorow-Smirnov test. Data with a 
normal Gaussian distribution were analyzed using 
Student´s t-test, data with a non-Gaussian distribu-
tion were analyzed using the Mann-Whitney U test. 
Categorical data were compared using the Chi-square 
test, except when the absolute number of events in 
each group was <5, in which case Fisher’s exact test 
was used. P-values ≤0.05 were considered as statisti-
cally significant.
Figure 1. Measurement of transcranial Doppler (TCD) flow velocity of the middle cerebral artery (MCA) with and without the 
intra-aortic balloon pump (IABP).
The picture shows a representative example of transcranial Doppler (TCD) flow measurement of the middle cerebral artery (MCA).
left: typical bimodal curve shows the increased mean cerebral blood velocity due to the increased diastolic cerebral blood flow while the IABP is 
operating.
right: normal cerebral blood flow pattern in the MCA while the IABP is turned off.
Table 1. Baseline characteristics.
Table 1 Overall LVEF>30%
(Group 1)
n=26
LVEF≤30%
(Group 2)
n=10
p-value
Age (years) 69.1 ± 10.1 68.3 ± 2.1 71.2 ±2.5 0.46
Female n (%) 10 (27.8)  7 (27)  3 (30) 0.86
Death n (%)  5 (13.9)  2 (7.7)  3 (30) 0.19
LVEF (%) 39.7 ± 11.2 44.3 ± 9.6 27.7 ± 3.4 <0.01
MAP with IABP in mmHg 81.5 ± 3.9 80.7 ± 3.7 81.8 ± 3.9 0.87
MAP without IAPB in mmHg 75.9 ± 2.3 76.0 ± 2.0 75.9 ± 2.5 0.62
Aspirin n (%) 36 (100) 26 (100) 10 (100)  
Clopidogrel n (%) 35 (97.2) 26 (100)  9 (90) 0.95
Heparin (%) 36 (100) 26 (100) 10 (100)  
HR with IABP (beats/min) 82.7 ± 16.4 80.9 ± 13.5 91.4 ± 16.9 0.44
HR without IABP (beats/min) 82.1 ± 16.0 80.4 ± 12.6 90.4 ± 17.8 0.47
TAPSE (mm) 22.1 ± 5.3 22.4 ± 1.2 20.8 ± 2.3 0.55
RVESP (mmHg) 36.9 ± 12.2 35.6 ± 2.6 40.3 ± 4.3 0.36
Dobutamine n (%) 39.2 ± 4.9 35.0 ± 4.8 50.0 ± 5.2 0.41
Noradrenaline n (%) 33.4 ± 4.7 27.0 ± 4.5 50.0 ± 5.2 0.19
Values represent numbers of patients (n) with percentages in parenthesis or mean ± standard error, as appropriate. LVEF: left ventricular ejection 
fraction; MAP: mean arterial pressure; IABP: intra-aortic balloon pump; HR: heart rate; TAPSE: tricuspid annular plane systolic excursion; RVESP: 
right ventricular systolic pressure.
514 Perfusion 29(6)
Results
Baseline characteristics of all 36 patients are shown in 
Table 1. The mean LVEF in Group 1 was 44.3% ± 9.6%, 
compared to Group 2 with a LVEF of 27.7% ± 3.4%. The 
implantation of an IABP was able to improve the mean 
cerebral blood flow in patients with a highly impaired 
left ventricular function as well as in patients with nor-
mal or slightly impaired LVEF. However, patients with a 
LVEF ≤30% had a significantly higher augmentation of 
cerebral blood flow with the IABP compared to patients 
with a LVEF>30%. The improvement of the cerebral 
blood flow, measured in MCA TDC flow velocity 
change, reached 20.9% (± 3.9%) in Group 2 vs. 10.5% (± 
2.2%) in Group 1 (p<0.05) (Figure 2). No severe compli-
cations (major bleeding or stroke) due to the implanta-
tion of an IABP were registered. Only two minor bleeds 
occurred in Group 1. The usage of sympathomimetic 
drugs was slightly higher in patients with highly 
impaired left ventricular function (Group 2), but did 
not reach significant values. The mean arterial pressure 
(MAP) before implantation of an IABP was similar in 
both groups. The MAP was increased only marginally 
after IABP implantation in both groups, without any 
significance.
Discussion
In the present study, we showed that an IABP augments 
cerebral blood flow. The increase of cerebral blood flow 
was significantly higher with 20% augmentation in sub-
jects with severe heart failure compared to patients with 
slightly reduced left ventricular function. The higher 
augmentation of cerebral blood flow in subjects with 
highly decreased left ventricular function might be due 
to the direct effect of the IABP, with displacement of 
blood volume and, consequently, the improvement of 
CO with the increase in coronary blood flow. Since right 
heart catheters were not routinely used during the pro-
cedures, we could only speculate that the compensatory 
increased in SVR might be reduced by the use of an 
IABP as it was previously reported.13 As the CBF was 
increased in a constant caliber of the main vessel, we 
assume that the patients on an IAPB had an increased 
CO. Since the decrease in mean arterial pressure in 
patients with an IABP was absent, we postulate a 
decrease in SVR (MAP = CO x SVR) as a possible expla-
nation for the presumably increased CO.
Both the decrease in left ventricular afterload and the 
increase in cerebral perfusion could be beneficial to 
patients with acute ischemic stroke and simultaneously 
existing severe heart failure. These data reflect other 
studies that proved an increased cerebral flow using 
external counterpulsation in a small cohort of sub-
jects.21,23 In subjects with vasospasm, the increase in cer-
ebral blood flow was achieved using a partial aortic 
obstruction by an intra-aortic inflation device which 
diverts blood flow from the systemic circulation toward 
the cerebral circulation.24 Contrary to the partial aortic 
obstruction, the IABP achieved an increase in mean 
CBF by augmenting, predominantly, the diastolic CBF. 
Normally, cerebral blood flow (CBF) is kept constant 
within a wide range (60 to 150 mmHg) of mean arterial 
pressures (MAP) whereas the CBF in patients with 
chronic heart failure can be reduced substantially. 
Experimental data suggested that the cerebral arteriolar 
dilatory capacity becomes nearly exhausted in patients 
with severe heart failure.24,25 It is probable that enhance-
ment of cardiac output rather than raised arterial blood 
pressure is able to increase CBF in patients with low car-
diac output. It has been demonstrated that reduced CBF 
in patients with severe heart failure could be normalized 
after successful heart transplantation.10 Therefore, the 
use of an IABP is safe even after the use of fibrinolytics 
and combined platelet aggregation inhibitors. The 
implantation of an IABP can be performed at the bed-
side and requires minimum expertise. The concomitant 
treatment of stroke and heart failure will be of vital rel-
evance in future. In these patients, the temporary use of 
an IABP could provide a special benefit by improving 
the cerebral blood flow. Limitations of this pilot study 
are: a relatively small number of subjects treated with an 
IABP, all the patients had cardiac diseases, but no strokes 
were investigated. Furthermore, no long-term outcome 
was noted. However, the use of an IABP seemed to be 
able to enhance cerebral blood flow, especially in 
patients with severe impaired heart function. The 
increase in mean CBF is presumably due to an aug-
mented diastolic CBF. The clinical relevance of an iso-
lated augmentation of diastolic CBF currently cannot be 
Figure 2. Improved cerebral blood flow in patients with 
LVEF≤30% using an IABP.
The chart shows the improvement of velocity time integral (∆VTI), 
which corresponds in this setting (∆CBF~VTI) to the improvement 
of cerebral blood flow in patients with an IABP according to their left 
ventricular function, LVEF >30% vs. LVEF ≤30%.
* p<0.05. Chart shows mean ± standard error.
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assessed.26,27 The common use of heparin anticoagula-
tion in patients receiving an IABP could be difficult in 
patients with acute ischemic stroke.28 However, no con-
vincing data for the necessity of anticoagulation in 
patients with IABP currently exists.29,30 The literature 
suggests that it is safe to omit heparinization when using 
IABP counterpulsation.31 Considering the fact that cur-
rent therapy options for increasing CBF barely exist, the 
temporary use of an IABP could provide a new treat-
ment option in selected patients with acute ischemic 
stroke and simultaneous severe heart failure, especially 
if there is a need to use a high dose of sympathomimetic 
drugs for maintaining an adequate blood pressure. 
Further studies have to address the question if the 
implantation of an IABP in subjects with acute stroke 
and severe heart failure could achieve a neurological 
improvement.
Declaration of conflicting interest
The authors have no conflicts of interest to declare.
Funding
This research received no specific grant from any funding 
agency in the public, commercial or not-for-profit sectors.
References
 1. Sims NR, Muyderman H. Mitochondria, oxidative 
metabolism and cell death in stroke. Biochim Biophys 
Acta 2010; 1802: 80–91.
 2. Kern R, Nagayama M, Toyoda K, Steiner T, Hennerici 
MG, Shinohara Y. Comparison of the European and 
Japanese guidelines for the management of ischemic 
stroke. Cerebrovasc Dis 2013; 35: 402–418.
 3. Saeed NP, Panerai RB, Horsfield MA, Robinson TG. Does 
stroke subtype and measurement technique influence 
estimation of cerebral autoregulation in acute ischaemic 
stroke? Cerebrovasc Dis 2013; 35: 257–261.
 4. Adams HP Jr., del Zoppo G, Alberts MJ, et al. Guidelines 
for the early management of adults with ischemic stroke: 
a guideline from the American Heart Association/
American Stroke Association Stroke Council, Clinical 
Cardiology Council, Cardiovascular Radiology and 
Intervention Council, and the Atherosclerotic Peripheral 
Vascular Disease and Quality of Care Outcomes in 
Research Interdisciplinary Working Groups. The 
American Academy of Neurology affirms the value of 
this guideline as an educational tool for neurologists. 
Circulation 2007 22; 115: e478–e534.
 5. Rordorf G, Cramer SC, Efird JT, Schwamm LH, 
Buonanno F, Koroshetz WJ. Pharmacological elevation of 
blood pressure in acute stroke. Clinical effects and safety. 
Stroke 1997; 28: 2133–2138.
 6. Rordorf G, Koroshetz WJ, Ezzeddine MA, Segal AZ, 
Buonanno FS. A pilot study of drug-induced hyperten-
sion for treatment of acute stroke. Neurology 2001; 56: 
1210–1213.
 7. Pullicino PM, Thompson JL, Sacco RL, et al. Stroke in 
heart failure in sinus rhythm: the warfarin versus aspirin 
in reduced cardiac ejection fraction trial. Cerebrovasc Dis 
2013; 36: 74–78.
 8. Corley SD, Epstein AE, DiMarco JP, et al. Relationships 
between sinus rhythm, treatment, and survival in the 
Atrial Fibrillation Follow-Up Investigation of Rhythm 
Management (AFFIRM) Study. Circulation 2004; 109: 
1509–1513.
 9. Freeman WD and Aguilar MI. Prevention of cardioem-
bolic stroke. Neurotherapeutics 2011; 8: 488–502.
 10. Gruhn N, Larsen FS, Boesga-ard S, et al. Cerebral blood 
flow in patients with chronic heart failure before and 
after heart transplantation. Stroke 2001; 32: 2530–2533.
 11. Moulopoulos S, Stamatelopoulos S, Petrou P. Intra-aortic 
balloon assistance in intractable cardiogenic shock. Eur 
Heart J 1986; 7: 396–403.
 12. Steg PG, James SK, Atar D, et al. ESC Guidelines for the 
management of acute myocardial infarction in patients 
presenting with ST-segment elevation. Eur Heart J 2012; 
33: 2569–2619.
 13. Prondzinsky R, Lemm H, Swyter M, et al. Intra-aortic 
balloon counterpulsation in patients with acute myo-
cardial infarction complicated by cardiogenic shock: the 
prospective, randomized IABP SHOCK Trial for attenua-
tion of multiorgan dysfunction syndrome. Crit Care Med 
2010; 38: 152–160.
 14. Jung C, Lauten A, Rodiger C, Krizanic F, Figulla HR, 
Ferrari M. Effect of intra-aortic balloon pump support 
on microcirculation during high-risk percutaneous 
intervention. Perfusion 2009; 24: 417–421.
 15. Sloth E, Sprogoe P, Lindskov C, Horlyck A, Solvig J, 
Jakobsen C. Intra-aortic balloon pumping increases renal 
blood flow in patients with low left ventricular ejection 
fraction. Perfusion 2008; 23: 223–226.
 16. Kammler J, Kypta A, Hofmann R, et al. TIMI 3 flow after 
primary angioplasty is an important predictor for out-
come in patients with acute myocardial infarction. Clin 
Res Cardiol 2009; 98: 165–170.
 17. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of 
thrombolysis, intra-aortic balloon pump counterpulsa-
tion, and their combination in cardiogenic shock com-
plicating acute myocardial infarction: a report from the 
SHOCK Trial Registry. SHould we emergently revascu-
larize Occluded Coronaries for cardiogenic shocK? J Am 
Coll Cardiol 2000; 36: 1123–1129.
 18. Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic bal-
loon support for myocardial infarction with cardiogenic 
shock. N Engl J Med 2012; 367: 1287–1296.
 19. Perera D, Stables R, Clayton T, et al. Long-term mortal-
ity data from the balloon pump-assisted coronary inter-
vention study (BCIS-1): a randomized, controlled trial of 
elective balloon counterpulsation during high-risk per-
cutaneous coronary intervention. Circulation 2013; 127: 
207–212.
 20. Barron HV, Every NR, Parsons LS, et al. The use of intra-
aortic balloon counterpulsation in patients with cardio-
genic shock complicating acute myocardial infarction: 
data from the National Registry of Myocardial Infarction 
2. Am Heart J 2001; 141: 933–939.
516 Perfusion 29(6)
 21. Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon 
counterpulsation and infarct size in patients with acute 
anterior myocardial infarction without shock: the CRISP 
AMI randomized trial. JAMA 2011; 306: 1329–1337.
 22. Purkayastha S, Sorond F. Transcranial Doppler ultra-
sound: technique and application. Semin Neurol 2012; 32: 
411–420.
 23. Alexandrov AW, Ribo M, Wong KS, et al. Perfusion aug-
mentation in acute stroke using mechanical counter-pul-
sation-phase IIa: effect of external counterpulsation on 
middle cerebral artery mean flow velocity in five healthy 
subjects. Stroke 2008; 39: 2760–2764.
 24. Lylyk P, Vila JF, Miranda C, Ferrario A, Romero R, Cohen 
JE. Partial aortic obstruction improves cerebral perfu-
sion and clinical symptoms in patients with symptomatic 
vasospasm. Neurol Res 2005; 27: S129-S135.
 25. Georgiadis D, Sievert M, Cencetti S, et al. Cerebrovascular 
reactivity is impaired in patients with cardiac failure. Eur 
Heart J 2000; 21: 407–413.
 26. Hansen JH, Schlangen J, Voges I, et al. Impact of after-
load reduction strategies on regional tissue oxygenation 
after the Norwood procedure for hypoplastic left heart 
syndrome. Eur J Cardiothorac Surg 2014; 45: e13–19.
 27. Varsos GV, Richards HK, Kasprowicz M, et al. Cessation 
of diastolic cerebral blood flow velocity: the role of criti-
cal closing pressure. Neurocrit Care 2014; 20: 40–48.
 28. Matute MC, Masjuan J, Egido JA, et al. Safety and out-
comes following thrombolytic treatment in stroke 
patients who had received prior treatment with antico-
agulants. Cerebrovasc Dis 2012; 33: 231–239.
 29. Jiang CY, Zhao LL, Wang JA, Mohammod B. 
Anticoagulation therapy in intra-aortic balloon coun-
terpulsation: does IABP really need anti-coagulation? J 
Zhejiang Univ Sci 2003; 4: 607–611.
 30. Cooper HA, Thompson E, Panza JA. The role of heparin 
anticoagulation during intra-aortic balloon counterpul-
sation in the coronary care unit. Acute Card Care 2008; 
10 :214–220.
 31. Pucher PH, Cummings IG, Shipolini AR, McCormack 
DJ. Is heparin needed for patients with an intra-aortic 
balloon pump? Interact Cardiovasc Thorac Surg 2012; 15: 
136–139.
